Outcomes of patients on dual-boosted PI regimens: experience of the Swiss HIV cohort study.

Cavassini, M.

doi:10.1089/aid.2010.0070

Titre

Outcomes of patients on dual-boosted PI regimens: experience of the Swiss HIV cohort study.

Type

article

Institution

UNIL/CHUV/Unisanté + institutions partenaires

Périodique

AIDS Research and Human Retroviruses

Auteur(s)

Osih, R.B.

Auteure/Auteur

Taffé, P.

Auteure/Auteur

Rickenbach, M.

Auteure/Auteur

Gayet-Ageron, A.

Auteure/Auteur

Elzi, L.

Auteure/Auteur

Fux, C.

Auteure/Auteur

Opravil, M.

Auteure/Auteur

Bernasconi, E.

Auteure/Auteur

Schmid, P.

Auteure/Auteur

Günthard, H.F.

Auteure/Auteur

Cavassini, M.

Auteure/Auteur

Contributrices/contributeurs

Battegay, M.

Bernasconi, E.

Böni, J.

Bucher, HC.

Bürgisser, P.

Calmy, A.

Cattacin, S.

Cavassini, M.

Dubs, R.

Egger, M.

Elzi, L.

Fischer, M.

Flepp, M.

Fontana, A.

Francioli, P.

Furrer, H.

Fux, CA.

Gorgievski, M.

Günthard, HF.

Hirsch, HH.

Hirschel, B.

Hösli, I.

Kahlert, C.

Kaiser, L.

Karrer, U.

Kind, C.

Klimkait, T.

Ledergerber, B.

Martinetti, G.

Müller, N.

Nadal, D.

Paccaud, F.

Pantaleo, G.

Rauch, A.

Regenass, S.

Rickenbach, M.

Rudin, C.

Schmid, P.

Schultze, D.

Schüpbach, J.

Speck, R.

de Tejada BM.,

Taffé, P.

Telenti, A.

Trkola, A.

Vernazza, P.

Weber, R.

Yerly, S.

Groupes de travail

Swiss HIV Cohort Study

Liens vers les personnes

Liens vers les unités

Maladies infectieuses

Médecine préventive hospitalière

ISSN

1931-8405

Statut éditorial

Publié

Date de publication

2010

Volume

26

Numéro

11

Première page

1239

Dernière page/numéro d’article

1246

Langue

anglais

Notes

Publication types: Journal Article ; Research Support, Non-U.S. Gov't Publication Status: ppublish. - WOS number: 000284311900012

Résumé

Dual-boosted protease inhibitors (DBPI) are an option for salvage therapy for HIV-1 resistant patients. Patients receiving a DBPI in the Swiss HIV Cohort Study between January1996 and March 2007 were studied. Outcomes of interest were viral suppression at 24 weeks. 295 patients (72.5%) were on DBPI for over 6 months. The median duration was 2.2 years. Of 287 patients who had HIV-RNA >400 copies/ml at the start of the regimen, 184 (64.1%) were ever suppressed while on DBPI and 156 (54.4%) were suppressed within 24 weeks. The median time to suppression was 101 days (95% confidence interval 90-125 days). The median number of past regimens was 6 (IQR, 3-8). The main reasons for discontinuing the regimen were patient's wish (48.3%), treatment failure (22.5%), and toxicity (15.8%). Acquisition of HIV through intravenous drug use and the use of lopinavir in combination with saquinavir or atazanavir were associated with an increased likelihood of suppression within 6 months. Patients on DBPI are heavily treatment experienced. Viral suppression within 6 months was achieved in more than half of the patients. There may be a place for DBPI regimens in settings where more expensive alternates are not available.